JP2023523083A5 - - Google Patents
Info
- Publication number
- JP2023523083A5 JP2023523083A5 JP2022565971A JP2022565971A JP2023523083A5 JP 2023523083 A5 JP2023523083 A5 JP 2023523083A5 JP 2022565971 A JP2022565971 A JP 2022565971A JP 2022565971 A JP2022565971 A JP 2022565971A JP 2023523083 A5 JP2023523083 A5 JP 2023523083A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- amino acid
- acid sequence
- seq
- bifunctional protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025115631A JP2025148434A (ja) | 2020-04-29 | 2025-07-09 | PD-1とTGF-βに対する二機能性タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010359751 | 2020-04-29 | ||
| CN202010359751.8 | 2020-04-29 | ||
| PCT/CN2021/089837 WO2021218895A1 (zh) | 2020-04-29 | 2021-04-26 | 针对PD-1和TGF-β的双功能蛋白 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025115631A Division JP2025148434A (ja) | 2020-04-29 | 2025-07-09 | PD-1とTGF-βに対する二機能性タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523083A JP2023523083A (ja) | 2023-06-01 |
| JP2023523083A5 true JP2023523083A5 (cg-RX-API-DMAC7.html) | 2024-05-07 |
| JP7711095B2 JP7711095B2 (ja) | 2025-07-22 |
Family
ID=78331777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565971A Active JP7711095B2 (ja) | 2020-04-29 | 2021-04-26 | PD-1とTGF-βに対する二機能性タンパク質 |
| JP2025115631A Pending JP2025148434A (ja) | 2020-04-29 | 2025-07-09 | PD-1とTGF-βに対する二機能性タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025115631A Pending JP2025148434A (ja) | 2020-04-29 | 2025-07-09 | PD-1とTGF-βに対する二機能性タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12668633B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4144763A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7711095B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230003178A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021263650A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022022020A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181579A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022013620A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021218895A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| CN116925223A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pd-1单克隆抗体及其衍生物和用途 |
| WO2023208191A1 (zh) * | 2022-04-29 | 2023-11-02 | 广东菲鹏制药股份有限公司 | 一种重组抗体及其应用 |
| WO2025251034A1 (en) * | 2024-05-31 | 2025-12-04 | Amgen Inc. | Purification method |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD120103A1 (cg-RX-API-DMAC7.html) | 1975-07-07 | 1976-05-20 | ||
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| ES2820768T3 (es) * | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN110050000B (zh) * | 2017-05-12 | 2022-07-26 | 苏州盛迪亚生物医药有限公司 | 含有TGF-β受体的融合蛋白及其医药用途 |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| CN119735681A (zh) * | 2018-04-25 | 2025-04-01 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| BR112020022145A2 (pt) | 2018-05-04 | 2021-01-26 | Merck Patent Gmbh | inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer |
| JP2021529557A (ja) | 2018-06-29 | 2021-11-04 | ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. | 抗腫瘍免疫チェックポイント調節因子アンタゴニスト |
| CN112672753B (zh) | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| EP3990116A1 (en) * | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| CN110734498A (zh) | 2019-10-15 | 2020-01-31 | 上海科棋药业科技有限公司 | 一种用于解除免疫抑制的融合蛋白及其应用 |
| JP7495489B2 (ja) * | 2019-10-21 | 2024-06-04 | ナンチン リーズ バイオラブス カンパニー,リミティド | PD-1およびTGFβを標的化する組換えタンパク質 |
-
2021
- 2021-04-26 KR KR1020227041823A patent/KR20230003178A/ko not_active Ceased
- 2021-04-26 EP EP21795280.3A patent/EP4144763A4/en active Pending
- 2021-04-26 US US17/922,122 patent/US12668633B2/en active Active
- 2021-04-26 WO PCT/CN2021/089837 patent/WO2021218895A1/zh not_active Ceased
- 2021-04-26 AU AU2021263650A patent/AU2021263650A1/en active Pending
- 2021-04-26 CA CA3181579A patent/CA3181579A1/en active Pending
- 2021-04-26 MX MX2022013620A patent/MX2022013620A/es unknown
- 2021-04-26 JP JP2022565971A patent/JP7711095B2/ja active Active
- 2021-04-26 BR BR112022022020A patent/BR112022022020A2/pt unknown
-
2025
- 2025-07-09 JP JP2025115631A patent/JP2025148434A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Forsberg et al. | Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen | |
| Fan et al. | Therapeutic application of anti-growth factor receptor antibodies | |
| JP2019107018A5 (cg-RX-API-DMAC7.html) | ||
| JP2022505871A5 (cg-RX-API-DMAC7.html) | ||
| HRP20220133T1 (hr) | Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe | |
| KR100909290B1 (ko) | 항암 항체 | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| FI3515938T3 (fi) | Monoklonaallisia vasta-aineita ohjelmoituun kuolemaan (PD-1) | |
| JP2020506971A5 (cg-RX-API-DMAC7.html) | ||
| KR20210100654A (ko) | Cd3 항체 및 그의 약제학적 용도 | |
| RU2015106147A (ru) | Антитела против kit и их применения | |
| CN112912109A (zh) | 通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症 | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JP2020530770A5 (cg-RX-API-DMAC7.html) | ||
| CN111995685B (zh) | 一种靶向her2和pd-1的双特异性抗体及其应用 | |
| IL272103B1 (en) | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer | |
| CN112969476A (zh) | 多特异性蛋白分子 | |
| KR20200120648A (ko) | 항pd-1/항her2 천연항체 구조 헤테로다이머계의 이중특이성 항체 및 그 제조방법 | |
| CN117157312A (zh) | 蛋白酶活化的多肽 | |
| JP2008508858A5 (cg-RX-API-DMAC7.html) | ||
| JP2024528935A5 (cg-RX-API-DMAC7.html) | ||
| CN110092832A (zh) | 抗ox40抗体及其用途 | |
| Sokolova et al. | Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency |